Baicalein suppresses the viability of MG-63 osteosarcoma cells through inhibiting c-MYC expression via Wnt signaling pathway

Molecular and Cellular Biochemistry

Volumn 405, Issue 1-2, 2015, Pages 187-196

  He, Nengbin ^a   Zhang, Zhichang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Baicalein; BANCR; c MYC; Osteosarcoma; Wnt; catenin

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BAICALEIN; BETA CATENIN; JANUS KINASE; MYC PROTEIN; WNT PROTEIN; FLAVANONE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNTING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE C MYC; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; WESTERN BLOTTING; WNT SIGNALING PATHWAY; BONE NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; OSTEOSARCOMA; TUMOR CELL LINE;

APOPTOSIS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLAVANONES; HUMANS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-MYC; WNT SIGNALING PATHWAY;

EID: 84929965087     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2410-6     Document Type: Article

References (34)

1. Raymond AK, Jaffe N (2009) Osteosarcoma multidisciplinary approach to the management from the pathologist’s perspective. Cancer Treat Res 152:63–84. doi:10.1007/978-1-4419-0284-9_4
2. Chou AJ, Geller DS, Gorlick R (2008) Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10:315–327
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
4. Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40:523–532. doi:10.1016/j.ctrv.2013.11.006
5. Nusse R, Varmus H (2012) Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 31:2670–2684. doi:10.1038/emboj.2012.146
6. Taketo MM (2004) Shutting down Wnt signal-activated cancer. Nat Genet 36:320–322. doi:10.1038/ng0404-320
7. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26. doi:10.1016/j.devcel.2009.06.016
8. Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA (2011) Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 82:211–216. doi:10.3109/17453674.2011.566141
9. Esumi T, Makado G, Zhai H, Shimizu Y, Mitsumoto Y, Fukuyama Y (2004) Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg Med Chem Lett 14:2621–2625. doi:10.1016/j.bmcl.2004.02.067
10. Singh T, Katiyar SK (2013) Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE(2)-mediated activation of beta-catenin signaling. PLoS One 8:e60749. doi:10.1371/journal.pone.0060749
11. Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L, Sha N (2014) Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One 9:e100893
12. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55:619–625
13. Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11–26. doi:10.1038/nrc3419
14. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP (2012) Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med 12:1244–1252
15. Hardt SE, Sadoshima J (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90:1055–1063
16. You L, Kim J, He B, Xu Z, McCormick F, Jablons DM (2006) Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect 19:27–31. doi:10.1358/dnp.2005.19.1.965871
17. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY (2001) Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152:87–96
18. Chae JI, Jeon YJ, Shim JH (2013) Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells. Oncol Rep 29:2318–2324. doi:10.3892/or.2013.2353
19. Jeong JJ, Lee JH, Chang KC, Kim HJ (2012) Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int J Oncol 41:1358–1364. doi:10.3892/ijo.2012.1582
20. Hahm ER, Arlotti JA, Marynowski SW, Singh SV (2008) Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 14:1248–1257. doi:10.1158/1078-0432.CCR-07-1926
21. Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J, Chen X, Wang X, Yuan Y, Tang M, Wen J, Wei Y (2008) Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res 22:1125–1132. doi:10.1002/ptr.2472
22. Kaldis P, Pagano M (2009) Wnt signaling in mitosis. Dev Cell 17:749–750. doi:10.1016/j.devcel.2009.12.001
23. Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3:36–41
24. Derksen PW, Tjin E, Meijer HP, Klok MD, Mac Gillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101:6122–6127
25. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ (2010) Wnt/β-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30:1868–1879
26. Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, Golemis EA, Liu W (2011) HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 30:2633–2643
27. Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y (2013) Long non-coding RNA: a new player in cancer. J Hematol Oncol 6:1–7
28. J-p Li, L-h Liu, Li J, Chen Y, X-w Jiang, Y-r Ouyang, Y-q Liu, Zhong H, Li H, Xiao T (2013) Microarray expression profile of long noncoding RNAs in human osteosarcoma. Biochem Biophys Res Commun 433:200–206
29. Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, Khavari PA (2012) BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res 22:1006–1014
30. Sun M, Liu X-H, Wang K-M, F-q Nie, Kong R, J-s Yang, Xia R, Xu T-P, Jin F-Y, Liu Z-J (2014) Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial–mesenchymal transition. Mol Cancer 13:68
31. Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang L, Tian Y, Han X, Tian D (2015) Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother 69:90–95
32. Jing L, Anning L (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36–42
33. Stavniichuk R, Drel VR, Shevalye H, Maksimchyk Y, Kuchmerovska TM, Nadler JL, Obrosova IG (2011) Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative–nitrosative stress and p38 MAPK activation. Exp Neurol 230:106–113
34. Q-m Zhou, Wang S, Zhang H, Y-y Lu, X-f Wang, Motoo Y, S-b Su (2009) The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin 30:1648–1658